Given that canonical driver mutation genes such as APC, TP53, and KRAS are shared by LCC and RCC, it is tempting to believe that activation of specific oncogenes and/or silencing of tumor suppressors may better explain their prognostic difference and also provide clues for treatment. This evidence concerns the gene KRAS and leukoencephalopathy with calcifications and cysts.